Gait and Balance Assessment and Therapy in Parkinson’s Disease
Tuesday, November 3rd, 2009Parkinson’s disease is a neurodegenerative disease of the central nervous system and is primarily characterized by cardinal motor symptoms such as tremor, bradykinesia (slowness of movement), and rigidity. Lower extremity symptoms such as gait and balance disturbances (initiating movement, freezing of movement, improper movement form), especially in advanced patients, can be very debilitating, leading to decreased mobility and independence, decreased quality of life, and an increased falling/hip fracture risk [1]. A positive PD diagnosis occurs when a minimum of two cardinal symptoms present themselves. However, less attention is given to gait and balance abnormality as it typically develops in the advanced stages of PD.
Standard clinical assessment of gait and balance based on a 0 (no severity) – 4 (high severity) scale is performed using a subset of the Unified Parkinson’s Disease Rating Scale (UPDRS) motor section. Tasks typically consist of foot stomping while seated, gait assessment while walking, arising from chair with arms crossed over the chest, and balance assessment while being pulled backwards. As gait is particularly sensitive to ON-OFF therapy state changes in PD and incorporates upper extremity function such as arm swing as well as rigidity and bradykinesia in lower extremities, gait analysis may be a reliable method of assessing overall motor function over time in PD [2].
When diagnosed with PD, the first line of treatment typically consists of L-Dopa medication to alleviate motor symptoms. However over time, drug effectiveness decreases, requiring the patient to increase dosage. Frequent and stronger side effects such as dyskinesias (uncontrolled arm movement) and unpredictable “on”/”off” episodes are cause for more invasive therapeutic intervention. Deep brain stimulation (DBS) has been widely recognized as an appropriate treatment option when medication no longer adequately alleviates motor symptom severity. Several therapy targets have been established for PD. Subthalamic nucleus (STN) and Globus Pallidus Interna (GPi) stimulation are recognized treatments for sustained improvement in tremor, rigidity, and bradykinesia [3, 4]. However the effects on gait disturbance are less understood. During DBS lead placement and post-evaluation, neurologists adjust several settings: electrode contact configuration and stimulation parameters (frequency, pulse width, and amplitude). Studies show that while high-frequency/high voltage stimulation improves cardinal symptoms, patients exhibit increased frequency of freezing episodes. However, stimulation at lower frequencies has demonstrated improved gait [5].
New PD gait therapies are being researched and developed and existing interventions further established. Another DBS target, the pedunculopontine nucleus (PPN), located near the brain stem plays an important role in locomotion function in animal models, specifically initiation and modulation of gait [6-8]. Patients with advanced stages of PD only exhibit mild improvement of freezing with standard medication such as L-Dopa [9, 10]. Preliminary studies of PPN surgeries off-medication marked a significant improvement of the UPDRS motor exam section III, specifically gait and postural qualities. In addition, the combination of STN and PPN DBS resulted in a further significant improvement. Despite promising results, PPN surgical intervention is currently in its infancy as little is known about the nucleus’ function in humans and how well animal model testing translates to human clinical trials [7].
2. Salarian, A., et al., Gait assessment in Parkinson’s disease: toward an ambulatory system for long-term monitoring. IEEE Trans Biomed Eng, 2004. 51(8): p. 1434-43.
3. Hamani, C., et al., Bilateral subthalamic nucleus stimulation for Parkinson’s disease: a systematic review of the clinical literature. Neurosurgery, 2005. 56(6): p. 1313-21; discussion 1321-4.
4. Krack, P., et al., Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med, 2003. 349(20): p. 1925-34.
5. Moreau, C., et al., STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. Neurology, 2008. 71(2): p. 80-4.
6. Garcia-Rill, E., et al., Locomotion-inducing sites in the vicinity of the pedunculopontine nucleus. Brain Res Bull, 1987. 18(6): p. 731-8.
7. Pahapill, P.A., et al., The pedunculopontine nucleus and Parkinson’s disease. Brain, 2000. 123 ( Pt 9): p. 1767-83.
8. Skinner, R.D., et al., Locomotor projections from the pedunculopontine nucleus to the spinal cord. Neuroreport, 1990. 1(3-4): p. 183-6.
9. Pullman, S.L., et al., Dopaminergic effects on simple and choice reaction time performance in Parkinson’s disease. Neurology, 1988. 38(2): p. 249-54.
10. Starkstein, S.E., et al., Evoked potentials, reaction time and cognitive performance in on and off phases of Parkinson’s disease. J Neurol Neurosurg Psychiatry, 1989. 52(3): p. 338-40.

